U-VUE Biomarker Datasheet - CD8
|Alternative Name:||T-lymphocyte differentiation antigen T8|
|Main cell types:||Cytotoxic lymphoid cells|
|Subcellular Location:||Plasma membrane|
|Positive control:||Tonsil, Spleen|
CD8 is primarily expressed on cytotoxic T cells, but it can also be expressed on cortical thymocytes, dendritic cells and NK cells. CD8 is a transmembrane glycoprotein that is a co-receptor for the T cell receptor (TCR). CD8 binds to MHC Class I to aid in antigen recognition and TCR-mediated activation. CD8 forms dimers of CD8ɑ and CD8β and clone C8/144B recognizes the alpha form of CD8.
IHC: Anti-CD8 antibody [C8/144B] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-CD8 antibody conjugate [C8/144B] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-CD8 antibody conjugate [C8/144B] staining normal tonsil FFPE tissue (brown). Nuclear counterstain in blue.
- Morrison, Carl et al. “Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.” Journal for immunotherapy of cancer, vol. 6,1 32. 9 May 2018. DOI: 10.1186/s40425-018-0344-8
- Sade-Feldman, Moshe et al. “Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.” Cell, vol. 176,1-2 (2019): 404. DOI: 10.1016/j.cell.2018.10.038
- Lechner, Axel et al. “Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.” Oncotarget, vol. 8,27 (2017): 44418-44433. DOI: 10.18632/oncotarget.17901
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.